$ALMS

Hardiman Roy C. sold $71K of ALMS

Hardiman Roy C. (Chief Business & Strategy Ofcr) sold 2,692 shares of ALUMIS INC. (ALMS) at $26.37 on 2026-08-03.

Original reporting
SEC EDGAR · Hardiman Roy C.
Published Aug 5, 2026, 10:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 5, 2026, 11:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALMS
Neutral
low confidence
Mentioned
$ALMS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALMSNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details (shares, price, total value, and post-transaction holdings) by an officer, with no pre-arranged 10b5-1 plan stated.

02

Market read

Traders may note insider selling as a minor sentiment datapoint, but there is no accompanying company-specific catalyst.

03

What to watch

The filing does not disclose intent, tax context, or whether other insiders are trading; without follow-on buys/sales patterns, signal quality is low.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-05, transaction dated 2026-08-03

Background

The article is an SEC Form 4 insider transaction disclosure for ALUMIS INC. (ALMS).

Company-level read

Ticker impact

$ALMSNeutralLow confidence
Context

ALMS insider Form 4 shows officer Hardiman Roy C. sold 2,692 shares for about $70,988 at $26.37 on 2026-08-03.

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

Form 4 insider sales are common and often non-informational; the filing lacks context on motives, and the transaction size is modest relative to typical market moves.

Market effects

No clear sector read-through from a single insider sale.

None indicated.

None indicated.

Counterpoint

The absence of a stated 10b5-1 plan does not necessarily imply negative information; insiders may sell for diversification, taxes, or planned liquidity needs.

Key entities

  • ALUMIS INC.

    Company whose insider transaction is disclosed on Form 4.

  • Hardiman Roy C.

    Chief Business & Strategy Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$JNJMedAI 8/10

Johnson & Johnson reports at least 72% PASI 90

Johnson & Johnson (JNJ) reported that its oral psoriasis drug ICOTYDE maintained at least 72% PASI 90 response rates through week 112 in the Phase 3 ICONIC-LEAD trial. JNJ shares rose 0.40% to $257.50. Alumis (ALMS) is also developing a psoriasis drug, envudeucitinib, with a planned U.S. application in Q4 2026.